BAKER BROS. ADVISORS LP Q2 2019 Filing
Filed August 14, 2019
Portfolio Value
$14.7B
Holdings
103
Report Date
Q2 2019
Filing Type
13F-HR
All Holdings (103 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | 50,057,277 | $3.5T | 23545.02% | |
| 2 | INCYIncyte Corporation | 31,976,193 | $2.7T | 18463.08% | |
| 3 | ONCBeiGene, Ltd. | 11,777,285 | $1.5T | 9920.98% | |
| 4 | ALXNAlexion Pharmaceuticals, Inc. | 8,258,068 | $1.1T | 7351.00% | |
| 5 | ACADACADIA Pharmaceuticals Inc. | 39,292,086 | $1.1T | 7137.84% | |
| 6 | AMRNAmarin Corporation plc | 41,544,288 | $805.5B | 5474.60% | |
| 7 | BMRNBioMarin Pharmaceutical Inc. | 7,589,294 | $650.0B | 4417.65% | |
| 8 | —Genomic Health, Inc. | 9,260,922 | $538.7B | 3661.14% | |
| 9 | ASNDAscendis Pharma A/S | 3,390,270 | $390.4B | 2653.15% | |
| 10 | MRTXEURMirati Therapeutics, Inc. | 2,513,462 | $258.9B | 1759.44% | |
| 11 | ARGXargenx SE | 1,019,557 | $144.3B | 981.02% | |
| 12 | ARRYEURArray BioPharma Inc. | 2,848,567 | $132.0B | 896.92% | |
| 13 | MDGLMadrigal Pharmaceuticals, Inc. | 1,169,278 | $122.6B | 832.88% | |
| 14 | NBIXNeurocrine Biosciences, Inc. | 1,415,283 | $119.5B | 812.09% | |
| 15 | HRTXHeron Therapeutics, Inc. | 6,018,104 | $111.9B | 760.33% | |
| 16 | KODKodiak Sciences, Inc. | 9,145,115 | $107.0B | 727.17% | |
| 17 | NVTA1EURInvitae Corporation | 3,902,421 | $91.7B | 623.25% | |
| 18 | 1T7Tricida, Inc. | 1,969,905 | $77.7B | 528.28% | |
| 19 | —Spark Therapeutics, Inc. | 751,927 | $77.0B | 523.18% | |
| 20 | BCELAtreca, Inc. | 3,532,760 | $66.6B | 452.33% | |
| 21 | —GW Pharmaceuticals plc | 370,845 | $63.9B | 434.48% | |
| 22 | IM8NInsmed Incorporated | 2,462,216 | $63.0B | 428.38% | |
| 23 | CERSCerus Corporation | 10,749,937 | $60.4B | 410.59% | |
| 24 | RYTMRhythm Pharmaceuticals, Inc. | 2,708,200 | $59.6B | 404.91% | |
| 25 | —Principia Biopharma Inc. | 1,787,807 | $59.3B | 403.26% | |
| 26 | —Audentes Therapeutics, Inc. | 1,506,438 | $57.0B | 387.61% | |
| 27 | ADPTAdaptive Biotechnologies Corporation | 1,165,411 | $56.3B | 382.55% | |
| 28 | BCRXBioCryst Pharmaceuticals, Inc. | 14,382,673 | $54.5B | 370.46% | |
| 29 | —Ra Pharmaceuticals, Inc. | 1,801,695 | $54.2B | 368.20% | |
| 30 | —MyoKardia, Inc. | 1,016,306 | $51.0B | 346.32% | |
| 31 | —DBV Technologies S.A. | 5,509,560 | $45.3B | 307.79% | |
| 32 | KRYSKrystal Biotech, Inc. | 1,034,674 | $41.7B | 283.17% | |
| 33 | CBAYUSDCymaBay Therapeutics, Inc. | 5,707,411 | $40.9B | 277.72% | |
| 34 | NBIX 2.25 05/15/24Neurocrine Biosciences, Inc. | 30,770,000 | $40.5B | 275.52% | |
| 35 | QUREuniQure N.V. | 517,700 | $40.5B | 274.96% | |
| 36 | KNSAKiniksa Pharmaceuticals, Ltd. | 2,799,577 | $37.9B | 257.61% | |
| 37 | —Zymeworks Inc. | 1,708,472 | $37.6B | 255.44% | |
| 38 | —Aquinox Pharmaceuticals, Inc. | 10,934,154 | $25.8B | 175.37% | |
| 39 | AXSMAxsome Therapeutics, Inc. | 772,286 | $19.9B | 135.15% | |
| 40 | XNCRXencor, Inc. | 428,120 | $17.5B | 119.09% | |
| 41 | MRUSMerus N.V. | 1,160,014 | $17.0B | 115.49% | |
| 42 | BMRN 0.599 08/01/24BioMarin Pharmaceutical Inc. | 15,000,000 | $15.6B | 105.79% | |
| 43 | —Acorda Therapeutics, Inc. | 2,011,189 | $15.4B | 104.84% | |
| 44 | —La Jolla Pharmaceutical Company | 1,559,231 | $14.4B | 98.02% | |
| 45 | —Aimmune Therapeutics, Inc. | 673,908 | $14.0B | 95.36% | |
| 46 | —Idera Pharmaceuticals, Inc. | 4,605,822 | $12.3B | 83.58% | |
| 47 | PTGXProtagonist Therapeutics, Inc. | 995,082 | $12.1B | 81.89% | |
| 48 | TPIVDEURMarker Therapeutics, Inc. | 1,500,000 | $11.9B | 80.74% | |
| 49 | AGLEUSDAeglea BioTherapeutics, Inc. | 1,713,604 | $11.7B | 79.77% | |
| 50 | ASMBAssembly Biosciences, Inc. | 803,246 | $10.8B | 73.64% | |
| 51 | GBYSangamo Therapeutics, Inc. | 999,823 | $10.8B | 73.18% | |
| 52 | CPRXCatalyst Pharmaceuticals, Inc. | 2,559,461 | $9.8B | 66.79% | |
| 53 | —Syros Pharmaceuticals, Inc. | 974,835 | $9.0B | 61.35% | |
| 54 | ALKSAlkermes plc | 400,000 | $9.0B | 61.27% | |
| 55 | —Dermira, Inc. | 906,943 | $8.7B | 58.92% | |
| 56 | BDQMAlbireo Pharma, Inc. | 250,000 | $8.1B | 54.78% | |
| 57 | APLSApellis Pharmaceuticals, Inc. | 313,725 | $8.0B | 54.03% | |
| 58 | MISTMilestone Pharmaceuticals Inc. | 266,667 | $7.2B | 49.20% | |
| 59 | ANABAnaptysBio, Inc. | 113,086 | $6.4B | 43.36% | |
| 60 | —Abeona Therapeutics Inc. | 1,288,235 | $6.2B | 41.85% | |
| 61 | HOOKGBPHOOKIPA Pharma Inc. | 892,857 | $6.0B | 40.84% | |
| 62 | ORTXUSDOrchard Therapeutics plc | 405,702 | $5.7B | 38.57% | |
| 63 | HALOHalozyme Therapeutics, Inc. | 299,969 | $5.2B | 35.02% | |
| 64 | —bluebird bio, Inc. | 40,000 | $5.1B | 34.58% | |
| 65 | —Bellicum Pharmaceuticals, Inc. | 2,677,818 | $4.6B | 30.94% | |
| 66 | —Menlo Therapeutics Inc. | 700,000 | $4.2B | 28.50% | |
| 67 | GTHXEURG1 Therapeutics, Inc. | 127,236 | $3.9B | 26.51% | |
| 68 | NGMUSDNGM Biopharmaceuticals, Inc. | 250,000 | $3.7B | 24.87% | |
| 69 | VKTXViking Therapeutics, Inc. | 425,000 | $3.5B | 23.98% | |
| 70 | XLRNAcceleron Pharma Inc. | 83,900 | $3.4B | 23.43% | |
| 71 | CRNXCrinetics Pharmaceuticals, Inc. | 132,985 | $3.3B | 22.60% | |
| 72 | GLPGGalapagos NV | 25,072 | $3.2B | 21.97% | |
| 73 | —Achillion Pharmaceuticals, Inc. | 1,095,359 | $2.9B | 19.95% | |
| 74 | VSAREURAravive, Inc. | 484,947 | $2.9B | 19.78% | |
| 75 | XBITXBiotech Inc. | 380,442 | $2.9B | 19.60% | |
| 76 | —Harpoon Therapeutics, Inc. | 214,285 | $2.8B | 18.93% | |
| 77 | —Forty Seven, Inc. | 250,000 | $2.6B | 18.01% | |
| 78 | AUTLAutolus Therapeutics plc | 156,773 | $2.5B | 17.15% | |
| 79 | YMABUSDY-mAbs Therapeutics, Inc. | 102,800 | $2.4B | 15.98% | |
| 80 | —Cyclerion Therapeutics, Inc. | 202,581 | $2.3B | 15.77% | |
| 81 | —Spring Bank Pharmaceuticals, Inc. | 613,144 | $2.3B | 15.38% | |
| 82 | NXTCNextCure, Inc. | 150,000 | $2.2B | 15.27% | |
| 83 | CTMXCytomX Therapeutics, Inc. | 194,377 | $2.2B | 14.82% | |
| 84 | —Molecular Templates, Inc. | 254,230 | $2.1B | 14.43% | |
| 85 | NTLAIntellia Therapeutics, Inc. | 128,538 | $2.1B | 14.30% | |
| 86 | IDYAIDEAYA Biosciences, Inc. | 200,000 | $2.0B | 13.54% | |
| 87 | CCXIEURChemoCentryx, Inc. | 207,029 | $1.9B | 13.08% | |
| 88 | —Constellation Pharmaceuticals, Inc. | 133,333 | $1.6B | 11.13% | |
| 89 | GLMDGalmed Pharmaceuticals Ltd. | 215,594 | $1.6B | 10.77% | |
| 90 | —Aileron Therapeutics, Inc. | 2,040,000 | $1.5B | 9.98% | |
| 91 | —Dova Pharmaceuticals, Inc. | 99,405 | $1.4B | 9.53% | |
| 92 | —Foamix Pharmaceuticals Ltd. | 498,189 | $1.2B | 8.06% | |
| 93 | —Sierra Oncology, Inc. | 2,000,000 | $1.1B | 7.61% | |
| 94 | —Adamas Pharmaceuticals, Inc. | 172,630 | $1.1B | 7.27% | |
| 95 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $1.0B | 7.10% | |
| 96 | RCUSArcus Biosciences, Inc. | 121,534 | $966.0M | 6.57% | |
| 97 | FLGTFulgent Genetics, Inc. | 125,000 | $835.0M | 5.67% | |
| 98 | —Affimed N.V. | 200,000 | $574.0M | 3.90% | |
| 99 | AQSTAquestive Therapeutics, Inc. | 99,600 | $418.0M | 2.84% | |
| 100 | —Sunesis Pharmaceuticals, Inc. | 556,665 | $405.0M | 2.75% |
Page 1 of 2Next